Biogen Inc. (BIIB) Earnings Call Transcript & Summary
February 15, 2023
Earnings Call Speaker Segments
Mike Hencke
executiveThanks, and good morning, everyone. Welcome to the Biogen call covering the fourth quarter and the full year 2022. Before we get started, please visit the investor section of biogen.com, where you'll find the earnings release along with the related financial tables, which include our GAAP financial measures and a reconciliation between GAAP and the non-GAAP financial measures we'll be discussing today. Tables one and two contain our GAAP financials, and table four provides a reconciliation of our GAAP to non-GAAP financial results; in our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage it internally. We've also posted slides on our website that accompany the discussions related to this call. I want to note that we'll be making forward-looking statements based on our expectations. Such statements carry certain risks and uncertainties, and our actual results may differ materially. For additional detail, please review the risk factors discussed in our SEC filings; joining me today are our President and Chief Executive Officer, Christopher A. Viehbacher, Dr. Priya Singhal, Head of Development, and our CFO, Mike McDonnell. As a reminder, during the Q&A portion of the call, we kindly ask that you limit yourself to one question. I'll now turn the call over to Chris.
Christopher Viehbacher
executiveThanks, Mike. Morning, everyone, and I appreciate you being here. It's great to have all of you with us today. Since coming to Biogen, this marks my first earnings call. Obviously, the company holds a powerful legacy as one of the early leaders in biotech, and there's plainly a solid base we can build on. At the same time, there's a pressing need to bring growth back to this company; a tremendous opportunity lies in front of us with the possible launch of 2 significant near-term launches, one in Alzheimer's and one in depression, plus we have multiple pipeline programs. We're going to share much more regarding how we plan to get back to growth. To start, I want to hand things over to Mike and ask Mike to walk through the fourth quarter full year financial results.
Mike Hencke
executiveThanks, Chris, and good morning to all of you. I'll walk you through a few highlights from our financial results in the fourth quarter, and whenever I make a financial comparison, it's against the fourth quarter of 2021. Total revenue in Q4 came in at $2.5 billion, which represents a 7% decline at actual currency and 4% at constant currency. Non-GAAP diluted EPS for the fourth quarter was $4.05, up 19% compared with the fourth quarter of 2021. MS product revenue reached $1.3 billion, a drop of 17% at actual currency and 14% at constant currency. That decrease largely reflects the effect of Tecfidera generics, along with ongoing declines in the interferons and some pricing pressure. We've continued to observe several TECFIDERA generics launching throughout multiple European countries; we expect a ruling from the European Court of Justice concerning our market protection by March 16th of this year. Separately, we are still enforcing our recently granted European TECFIDERA dosing patent, which runs until 2028. We're also continuing to enforce our IP for TYSABRI. We've filed suit against Polpharma and Sandoz to enforce those rights and have sought a preliminary injunction against the U.S. launch of the Sandoz and Polpharma biosimilar. On the subject of potential supply constraints for VUMERITY, we believe the previously reported manufacturing issues at our contract manufacturer have been resolved. Right now we're working on obtaining regulatory approvals for a secondary source of supply. We don't expect a supply shortage in 2023. Turning now to SMA. Global SPINRAZA revenue was $459 million, which is a 4% increase at actual currency and 10% at constant currency; within the U.S., SPINRAZA revenue rose 5% compared with the prior year, and we continue to believe we may be seeing signs of stabilization. Beyond the U.S., revenue grew 4% at actual currency and 12% at constant currency, driven by continued growth primarily in our Asian markets, which was partly offset by competition in Europe. Biosimilars revenue was $175 million, a 21% decline at actual currency and 15% at constant currency; that reflects continued pricing pressure and some net pricing adjustments during the quarter. Total anti-CD20 revenue of $448 million was up 8% compared with the prior year. Revenue from OCREVUS royalties grew 19%, which was partially offset by a 14% revenue decline related to our profit share on Rituxan. The Rituxan decline stemmed from biosimilar competition. Turning to expenses for the fourth quarter, non-GAAP cost of sales was $571 million, which is 22% of revenue, and that figure includes $36 million of idle capacity charges. Eisai's share of those charges appears as part of the collaboration profit-sharing line, and it is not included in cost of sales. Fourth quarter non-GAAP R&D expense was $602 million, compared with $700 million in the fourth quarter of 2021. The fourth quarter of 2021 included approximately $110 million in payments tied to some business development transactions. On a non-GAAP basis, SG&A came in at $632 million. That's down from $785 million during 2021's fourth quarter. The main reason for this drop in SG&A expense was the cost savings initiatives we'd already told you about. We're still set to hit the 1 billion in cost savings initiatives we announced earlier, and I'll say more about that once I get to our 2023 guidance. Turning to the balance sheet, we closed out the quarter holding $5.6 billion in cash and marketable securities. Our debt stood at $6.3 billion, with net debt of roughly $700 million. Just a reminder that we anticipate bringing in another $1.25 billion across the coming 15 months from selling our equity stake in Samsung Bioepis. Roughly $813 million of that is scheduled to arrive in April of this year. All told, we're still in a very strong financial position, with substantial cash and financial capacity to put toward growing the business over time. I'll go over our guidance assumptions along with some key accounting considerations for 2023 later in the call; for now, I'll hand the call back to Chris.
Christopher Viehbacher
executiveThanks, Mike. I've got that in front of me. Not long ago, Biogen marked 45 years since its founding, and this is an organization whose foundations truly rest on multiple sclerosis. It also had a few hemophilia offerings before those were separated off into Bioverativ. A number of you might remember that from back then. Then there's SPINRAZA. At this point, we genuinely have to ask ourselves how the business gets transformed. From my own conversations with quite a few neurologists, I know directly that our MS treatments are still viewed as the best available. Clearly, the competitive landscape has gotten far tougher. So we truly have to figure out how the business grows going forward. Right now, an incredible opening exists for us thanks to a pair of new products. As a lot of you are aware, I've spent many years in this industry, and getting the chance to launch two big products rather than just one is something that hardly ever comes along. And these aren't ordinary products — they're therapies that are genuinely transformative within the areas they treat. Naturally, I mean LEQEMBI and zuranolone. We've also got products already on the market. VUMERITY still has room to grow, SPINRAZA still has room to grow, and my view is that we need a new way of approaching them, working to reignite growth for both of those brands. Plenty of you will remind me that BIOGEN's cost base sits higher than what most of its competitors carry, and we have to approach that in a far more systematic way. Part of it could mean bringing costs down. Part of it is really about realigning things with the new growth options. Beyond that, we also have to examine the R&D pipeline. At the moment, what sits in R&D doesn't earn us much recognition, and Priya will walk you through several different products that we believe hold a great deal of promise. At the same time, you know, the neurology franchise centers on slowly progressing diseases. What that means, inevitably, is costly research conducted over many years. Beyond that, some of the programs in our portfolio center on Phase three trials that are essentially proof of concept in nature, and that fact alone raises the risk profile. My view is that we ought to think about how the R&D pipeline gets balanced from here on. Finally, it's my belief that we — and really, any company — should remain open to growth possibilities originating from outside our walls. Historically, this organization never truly pursued that as a central strategy. Yet I genuinely think that as we expand into further areas such as immunology, rare diseases, and psychiatry, opportunities may arise to bolster those franchises through external growth. Everyone is aware that LEQEMBI received accelerated approval in the United States at the start of January. The same day that happened, we filed for full or traditional approval. I should also give credit to our partner, Eisai, because in a really short window, they didn't just file for traditional approval on the exact day accelerated approval came through — they also, within just a few weeks, filed in Europe, filed in Japan, and then began a rolling submission in China. Obviously, in the near term, the U.S. launch will be fairly limited until reimbursement arrives, which is expected to occur once traditional approval has been secured. Once we receive confirmation of filing from the FDA, at that moment, we'll find out if we've got a priority review or not. Per the agreement's terms, Eisai holds principal responsibility and takes the lead on all discussions with CMS. As a lot of you likely have heard, Eisai has stated they're hoping for broader reimbursement once traditional approval comes, and that might arrive as early as this summer. As you're aware, what we're launching here isn't a round white pill. You know, a PET scan or a lumbar puncture is needed to confirm diagnosis. We're going to face infusion capacity limitations. Neurologists are already occupied treating patients with other conditions. Someone will inevitably ask if we've got enough neurologists on hand to grow the number of patients we can treat. A great deal of work lies ahead in the short term. That said, you know, one thing that keeps getting raised — and this is going to be the central topic for CMS — is that question. From my perspective, the sum of boxes — the CDR Sum of Boxes — isn't truly the lens through which we assess benefit for patients here. When I speak with doctors who treat Alzheimer's patients, what nearly all of them want to know is: "Am I still able to drive? Can I feed myself? Can I get dressed on my own? Can I still find joy being with my family?" And naturally, the question arises: how do I avoid becoming a burden on those around me? If you examine everyday activities closely, the data showed a 37% gain compared with placebo. For me, that's precisely where this product delivers genuine value. Turning to Alzheimer's, there's another point I want to really emphasize today: what we're dealing with isn't merely a product launch. Both a present and a future exist here. Obviously, right now, all eyes will be on the early sales figures for LEQEMBI, and the issue there becomes getting past certain infrastructure obstacles that we just discussed. A great deal of physician education will be needed regarding safety and diagnosis, and the infrastructure must grow so that PET scans or CSF testing can be delivered. You know, this really is unlocking an entirely new area. It's a brand-new vista, for patients as well as physicians. You know, my mind goes back ten years, when there were lots of setbacks with medications being created to reduce amyloid. Basically, people had given up on the idea that this might succeed. As it happens, the PRIME study from Biogen, which began about a decade ago, ultimately demonstrated that this strategy still held promise. Naturally, it's the Clarity AD trial that has truly proven how important plaque removal is and how it might affect cognitive decline. My view is this will set off an entire surge of research and development, though other developments will come too. I mean, even the work we ourselves are doing. Obviously amyloid is one piece, but additional modalities like tau are coming; and Priya will discuss our own possible tau-based answer. We're also examining this — the study really centered on 18 months of therapy. What occurs once those 18 months finish? Data already exists showing that remaining on the drug delivers ongoing benefit. As a matter of fact, Eisai intends to file before this year's Q4 ends for an indication covering maintenance treatment. Another of the most fascinating discoveries — and I've been, you know, clearly working to get myself educated about Alzheimer's across the past 90 days — is that plaque burden reaches its peak right before symptoms appear.
Christopher Viehbacher
executiveThink about how much better it would be if we could intervene sooner, and as it happens, a study named AHEAD is examining patients who are preclinical or presymptomatic, which might prove very interesting. Naturally, to accomplish that, additional tools such as blood-based biomarkers and other biomarkers will matter greatly; we will need to make treatment far more convenient, and subcutaneous formulations are already being developed. So my expectation is that you will witness a deluge of data across the coming 3 to 5 years as novel modalities and novel approaches to treating Alzheimer's patients emerge. As you can see here, the AHEAD study began in 2020 and focuses on presymptomatic individuals. A physician who treats Alzheimer's once told me, "We used to view Alzheimer's as spanning 7 to 8 years, really from when symptoms appeared until, tragically, death. These days they're examining it across a 25-year frame since we understand that plaque accumulates over time." In reality, what we currently label early stage Alzheimer's, with that mild cognitive improvement, isn't truly early. By the time MCI appears, it's actually already fairly advanced. We've already discussed the possibility of maintenance dosing and various modalities. This will be a really thrilling space as things progress. Another thrilling space is major depressive disorder. There are 21 million individuals living with this condition. Each day you come across reporting on the significant worries surrounding mental health in society. In fact, STAT published a piece just yesterday regarding how many younger people are dealing with depression, feeling sad, and even having suicidal thoughts. Clearly, new treatments are needed. More than 400 million prescriptions get written annually for MDD and other mental health conditions. What we observe is a tremendous amount of switching among therapies. There's considerable worry about side effects. These current medicines take quite a while to take effect. In my own opinion, there's a huge amount of unmet need. I was at GlaxoSmithKline back when we had Paxil and Wellbutrin, so I'm quite acquainted with what today's treatments are capable of and where they fall short. Postpartum depression is yet another substantial area of unmet need. One in eight mothers — we just saw a heartbreaking case that many of us around Boston are watching — and it plainly shows there's a genuine need for a fresh approach, a fresh treatment here; this may not be where a large commercial opportunity lies, but there is a huge societal need, and I believe zuranolone can bring about a major change here. We've received priority review, and we now have a PDUFA date in August. As you're aware, we can't launch right away since a D.E.A. will be required. We need to review the drug's scheduling prior to launch, so the target is now later in the year. One thing I find interesting is that every so often I see media coverage about zuranolone's controversial data, since six out of seven trials were positive. Folks, back when Paxil was being developed years ago, we needed six phase three studies just to get two that worked. The placebo effect here is tremendous, and that's the reason many companies actually walk away from mental health. When six out of seven came in, I thought, "This is absolutely terrific." There's a pretty exciting opportunity sitting here, in my view. We won't necessarily pursue every patient type, and we're doing extensive market research. The SHORELINE Study finishes today, and it will tell us who the right patient is for this. The label, obviously, will tell us who we're interested in. There are many unresolved symptoms of depression out there. For MDD patients with elevated anxiety, we won't clearly have an anxiety indication, but we're. That's one area of MDD patients we'll be focusing on, along with those who are adherence challenged. Turning back to existing drugs, I'll simply note that Biogen has enjoyed enormous success with SPINRAZA. Looking at it, plenty of potential patients remain untreated — adults as well as pediatric patients; we're going to take a fresh look at how coverage of this product can be improved. Obviously, it's an intrathecal product, which isn't necessarily the most convenient. You may have noticed we just entered a collaboration with Alcyone for a new device that would make things more convenient for patients who don't want to endure the numerous lumbar punctures; we are examining costs. That means examining the profitability of our MS franchise. Can some of these costs be shifted toward supporting our new product launches? We have a biosimilars business, an important business; it's part of how we create the economies for the healthcare system to afford new businesses. We're examining whether more can be done with that business or perhaps whether others should own it. We're prioritizing the near-term opportunities and truly examining our cost base on a systematic basis. Priya's going to discuss the risk profile and productivity of the R&D pipeline. As I mentioned earlier, we have appointed Priya as Head of Development. I'd like to take this opportunity to congratulate her on that; we're also looking for a new Head of Research. While we have a lot going on, we will continue to evaluate external growth opportunities. With that, Priya, why don't we talk about R&D?
Priya Singhal
executiveThanks, Chris. As Chris mentioned, we're moving LEQEMBI forward with Eisai, establishing a base in Alzheimer's disease, alongside zuranolone with Sage — both important late-stage assets and engines of growth. With Sage, we also shared that the FDA has accepted zuranolone for MDD and PPD under priority review. The PDUFA date falls on August fifth. The FDA grants priority review to applications for drugs that, if cleared, would deliver meaningful gains in how effectively or safely a serious condition is treated, diagnosed, or prevented. Alongside these steps, we're continuing to make headway on reprioritizing R&D, and today I'll walk through a handful of standout items from several pipeline programs — in Alzheimer's disease, lupus, and ALS. As Chris mentioned, we're pushing ahead with a wider Alzheimer's pipeline, and enrollment has begun in the phase 2 CELIA trial of BIIB080 for early Alzheimer's disease. Earlier clinical findings, among them results from our own phase 2 gosuranemab, indicate that going after extracellular tau by itself does not do enough to impact intracellular tau tangles. BIIB080 goes after tau mRNA in order to lower every form of the tau protein, after translation. In preclinical work, we observed that ASO knockdown of tau in the transgenic mouse model of neurodegenerative tauopathy reversed tau pathology, averted hippocampal volume loss, and prevented neuronal death; this slide shows the phase 1B trial results for BIIB080 in mild AD. BIIB080 was generally well tolerated, and we saw a reduction in CSF total and p-tau that depended on both time and dose. Total tau kept falling 16 weeks after the final dose, dropping 50% from baseline; this early data encouraged us, and we're eager to share the data details from this 1B study at ADPD next month. As I noted, our phase 2 CELIA study began in 2022. It incorporates multiple dosing paradigms — three doses, given every 12 or 24 weeks. Assessments will look at several dimensions of Alzheimer's disease: cognition, function, and biomarkers. We think CELIA could yield valuable insights about tau's role in Alzheimer's disease. Moving on. Biogen has drawn on very deep scientific know-how in immunology, and that's how the MS franchise came about. Next I want to cover our two phase 3 lupus programs. The first is dapirolizumab pegol, which is in phase 3 through our collaboration with UCB; we also have litifilimab, or BIIB059, our wholly owned anti-BDCA-2 monoclonal antibody. Each is a potential first-in-class molecule in SLE. SLE is an autoimmune condition that may involve multiple organs and can result in serious organ damage and morbidity, particularly among non-Caucasian patients. Litifilimab could also become a first-in-class therapy for CLE. CLE, or cutaneous lupus erythematosus, is a skin-based autoimmune disease and may occur without systemic manifestations. Chronic CLE comes with severe skin damage and a diminished quality of life. No new treatment has been approved specifically for CLE in nearly 17 years. Turning to the phase two LILAC trial, the CLE portion achieved its primary endpoint, and those findings appeared last summer in the New England Journal of Medicine. Given those encouraging data, we launched the phase 2/3 AMETHYST trial evaluating litifilimab in CLE. Lupus hits underrepresented groups at disproportionate rates, so enrollment targets across the litifilimab trials have been set to mirror the high prevalence seen in African American and Hispanic or Latino communities. I'll move next to ALS. This is a devastating, progressive neurodegenerative disease. The SOD1 form is an ultra-rare genetic subtype affecting roughly 330 people in the U.S. Although the VALOR phase three trial of tofersen in SOD1 ALS missed its primary endpoint, our 12-month data from VALOR and its open-label extension were published in the New England Journal of Medicine last year. In those findings, among individuals who started tofersen earlier, we saw a sustained reduction in neurofilament, a marker of axonal injury and neurodegeneration. We likewise saw a slower decline across measures of clinical and respiratory function, plus strength and quality of life. With a PDUFA action date of April 25, 2023, Biogen could potentially bring a genetically targeted therapy to people suffering from SOD1 ALS. FDA recently announced the March 22, 2023 date for the advisory committee meeting on tofersen. EMA has accepted the marketing authorization application for tofersen for review in the European Union. Stepping back to a higher level, as Chris mentioned, our aim is to rebalance the R&D pipeline. To that end, we've built a framework guiding our decision-making, with the focus on pre-proof of concept programs; for instance, we are investing to win in programs where biological confidence runs high, such as BIIB080, while continuing a systematic, data-driven approach in this program to learn and de-risk. For some programs, we may also opt to halt development because of regulatory development or commercialization challenges. Recently discontinued programs include vixotrigine in neuropathic pain and oral orelabrutinib in MS. At the same time, several focus areas exist to help raise pipeline productivity and lower risk. First is de-risking and improving probability of success within the pre-proof of concept portfolio. Second is strengthening the roll-off and capabilities for translational science and, importantly, our overall emphasis on value generation rather than achievement of operational milestones alone. In closing, with key assets in Alzheimer's disease, depression, and lupus, we believe the Biogen pipeline can potentially deliver significant growth over the medium and long term. I'll now hand the call back over to Mike.
Mike Hencke
executiveThanks, Priya. Now I'll walk everyone through the guidance ranges we're giving for 2023, cover a few of the main assumptions behind them, and after that we'll take your questions. For the full year 2023, our expectation is that revenue will fall in the mid-single-digit % range compared with what we reported for 2022, and that non-GAAP diluted earnings per share for the full year 2023 will land somewhere between $15 and $16. I want to call out a number of dynamics we're anticipating in 2023. To start, the guidance we're providing rests on an assumption that the Court of Justice of the European Union issues a favorable ruling on regulatory data protection for Tecfidera. Like I mentioned before, we're expecting that ruling on March 16th, 2023, but obviously there's no way for anyone to predict what the court's decision will be. That same outlook also factors in a small amount of end market revenue for LEQEMBI in 2023, with commercialization costs exceeding revenue. For LEQEMBI in the U.S., Biogen's portion of net commercial profits and losses will show up as part of total revenue, and yes, we expect that to be a headwind for our revenue in 2023. As a reminder, back in 2022 we amended the collaboration agreement we have with Eisai covering Aduhelm, and because of that, starting in 2023 we hold sole decision-making and commercialization rights together with a substantial majority of the economics. Eisai will get a tiered royalty and will stop sharing in expenses tied to Aduhelm. That gives rise to two important considerations for 2023. The first: we anticipate incurring roughly $150 million-$200 million in excess capacity charges during 2023. Biogen will bear all of that. During 2022, we incurred $119 million of idle capacity, and Eisai reimbursed $55 million of that figure. Looking ahead to 2023, we anticipate cost of sales will represent a larger share of revenue than the 22.4% recorded in 2022. Product mix, combined with the dynamic I just walked through, drives that. We think this strain on cost of goods sold will be especially noticeable in the earlier portion of the year. There's a second effect from the amended Eisai agreement: we will no longer share Aduhelm R&D costs, and versus 2022, that should add roughly $100 million to R&D expense in 2023. For the entire year, our operating expenses—both SG&A and R&D—will incorporate the $1 billion in cost-cutting steps we announced earlier. Roughly $300 million out of those savings is slated to be put back into the business to back the Zuranolone launch along with other new products. Compared with full year 2021 operating expenses of about $5.2 billion, the upshot should be $700 million in net operating expense savings. Regarding IMRALDI, we keep watching for possible supply constraints; no stock outs are baked into our guidance, though that possibility remains a risk. We'd also like to flag a few important seasonality dynamics. I want to start by noting that, for our US MS business, the opening quarter of the year tends to be the softest one — it comes in below Q4 — and the reasons are how the channel behaves as well as bigger rebates and allowances. A portion of Spinraza's Q4 2022 increase was tied to the timing of specific shipments. Another thing to remember is that Ocrevus's royalty rate goes back to its starting point each January and then steps up as the year's sales grow. On top of that, we expect operating expenses to run higher in the early part of the year, because a number of our cost savings programs won't fully kick in until later in 2023. As is our usual practice, we're taking the position that currency exchange rates from December 31st, 2022 will remain unchanged throughout the year, after accounting for our hedging programs. Our press release contains further significant assumptions that guide our outlook. Prior to concluding, I'd like to highlight some notable accounting items related to LEQEMBI and zuranolone. Given that LEQEMBI has secured accelerated approval in the U.S., the 50% portion of net commercial profits and losses belonging to Biogen — encompassing in-market revenue, minus cost of goods, royalties, and SG&A — will be reported within total revenue. As I mentioned, we anticipate this figure will be negative in 2023, because we expect commercial expenses to surpass revenue. For markets beyond America, the half of commercial costs we carry—50%—will continue to sit under SG&A until LEQEMBI secures clearance country by country. On a different note, the portion Biogen owes for worldwide LEQEMBI research and development spending, also 50%, is going to remain inside R&D expense, and that holds true regardless of whether approval has come through or not.
Christopher Viehbacher
executiveTo wrap up, regarding LEQEMBI, we're producing the drug substance at our facility located in Solothurn, Switzerland, which belongs to Biogen. Inventory gets capitalized by us up until the point it's sold over to Eisai — when that happens, we'll book contract manufacturing revenue along with the related cost of goods sold, and the gross margin on that will be minimal. When it comes to Zuranolone, that's likewise a 50/50 split of profits across the US together with Sage Therapeutics, our partner. Before any regulatory approval comes through, our portion of R&D plus SG&A expenses gets recorded under their corresponding line items, netted against reimbursement either to Sage or from Sage. Once approval in the U.S. is granted, Biogen is going to record the full 100% of Zuranolone product revenue, cost of goods, and SG&A, after which we'll account for Sage's 50% share of either profits or losses within Biogen's collaboration profit-sharing line. To close things out, bringing Biogen back to sustainable growth stands as our top objective. We hold the view that the possible introductions of LEQEMBI and Zuranolone, together with the remainder of our pipeline plus our robust balance sheet, give us what's needed to reach that objective. On top of that, we're putting in a great deal of effort toward boosting our operating efficiency and stay dedicated to generating long-term value on behalf of our shareholders. Having said all that, we'll now take questions on the call.
Salveen Richter
analystMorning, and thanks for letting me ask. I wonder if you could share what the possible timelines look like for the NCD reconsideration regarding LEQEMBI. Looking back at history, that kind of process has tended to run roughly nine months, but what's the earliest point it might get underway? Is it possible for it to begin before we have full approval? And how would we find out that it's been kicked off? Thanks.
Christopher Viehbacher
executiveYeah, appreciate the question. Honestly, I'm not convinced, to begin with, that what happened previously will really be the deciding factor in this case. My sense is that the circumstances here are pretty unique. Eisai and CMS are currently in talks and discussions. CMS is free to make whatever call it wants. The sense we get is that they'd rather hold off until a traditional approval exists, and after that, we'll find out. Whether a registry will be required or not is something we simply can't say right now. What I can tell you is that the tone across the wider community strikes me as quite different from what we saw around ADUHELM. The American Academy of Neurology, for instance, has written to CMS backing reimbursement. You've also got members of Congress weighing in. From what I can tell, the neurology community at large views the Clarity data as highly persuasive when it comes to the impact. CMS will of course make its own choices, but I do think a growing consensus has formed that this medicine is one a broad population badly needs. Eisai has said it hopes broader reimbursement will arrive once traditional approval is in hand.
Christopher Viehbacher
executiveThanks.
Mohit Bansal
analystExcellent. Thanks for fielding my question. Perhaps I could ask about reductions in expenses. I realize that earlier in the year, you mentioned trimming costs. If one runs the numbers, it's obvious that the cost structure for the product portfolio is quite elevated. Have you given thought to what your long-term target operating margin profile looks like? How many additional reductions are possible? Are there any timelines for when we might learn about this? Since, as you're aware, you also brought up roughly $200 million of declining spend here. You indicated that you'd likely prioritize and work out whether you wish to continue spending that money. Could we discuss the timelines for that a bit, given that you're now in the business review mode? Thanks.
Christopher Viehbacher
executiveWell, when it comes to OpEx, there are two major buckets, correct? There's R&D along with SG&A; on the R&D side, we're conducting this entire prioritization exercise. That means if you wish to conserve money to some extent, you might need to discontinue certain programs. That isn't something you'd want to rush. You have to examine every program in depth, establish probabilities of success, cost to complete, plus a whole bunch of other factors. There's an infrastructure component to R&D that we'll be examining as a priority. Then there's SG&A. When it comes to sales and marketing, clearly, the bulk of that spending is really going toward the MS franchise; at present, the MS franchise still underpins most of our revenue in the business. One must be cautious regarding how much we wish to lower that spend by. Plainly, that's a shrinking revenue base. What you're truly going to witness, I think, is a shift of some of those resources toward supporting the launch. Right now there are hundreds of millions of dollars flowing among Eisai, Sage and Biogen behind the pre-launch activities this year for LEQEMBI and zuranolone; those are plainly strategic products for all of the companies, and we truly need to support the launches; we must strike the right balance and not see a decline in MS sales beyond what we already see. There's GNA, and we'll be taking a close look at that this year. You know, you're going to see some cost reductions, but there will also be some new investments. It's somewhat difficult to say at this point where we'll end up on margins. You know, if you strip out the royalty and collaboration income and do the OPEX to sales ratios, we're plainly higher than most of our peer companies. Given that we have a fairly mature product profile of high value, low volume products, you know, we should be more profitable. You know, the company's already taken 1 billion out, so that means more cost savings have to be done thoughtfully. You'll get further updates from us as the year goes on regarding that. We recognize the need for our cost structure to deliver greater productivity than it currently does. Regarding ADUHELM, as you're aware, we're going to examine the EMBARK data, which covers the long term. That should provide insights not only about ADUHELM but also regarding our thinking on treating patients over a longer horizon with amyloid-reducing antibodies. We also must determine precisely what the competitive landscape looks like. What I can share is that no commercial resources are behind ADUHELM. LEQEMBI is where our attention sits. In our view, that's the product best suited for patients. We've made a commitment to the FDA to conduct this confirmatory study, so careful consideration is required on our part. Let me be clear: strategically speaking, LEQEMBI represents our top priority without question, and ADUHELM isn't being actively commercialized in any market.
Colin Bristow
analystHi there, good morning. I appreciate you taking my question. Chris, welcome aboard. Regarding how you currently see the business and the pipeline, what should our expectations be on timing — specifically around the possibility of strategic moves involving ADUHELM, and then, more generally on business development, when will you have clearly pinpointed the target you'd potentially be ready to pursue? And as part of this same question, could you describe where your interest stands right now regarding biosimilars? Thank you.
Christopher Viehbacher
executiveRegarding R&D, you've got quite a few projects that have been running for several years. We actually have several products sitting in phase three that are really proof of concept studies. If we completely ignore ADUHELM, there are three products we're working on where we didn't have safety or efficacy information from a successful phase two trial. Each of those programs, in my opinion, warrants serious consideration. It requires a fair amount of time, and the inevitable question becomes: how much funding do we need to commit to get to the next milestone, and is it genuinely worth it? Are there other ways we could run the study? Is there a way to reduce the risk? That probably takes us into the summer, I think, before we can really make many decisions on that front. As for biosimilars — the team is very capable, and they've created a thriving business. So from my perspective, Biogen is an organization built around novel therapies. We're certainly not a massive enterprise, which means we have to stay focused. We're evaluating which business model makes the most sense for us. As I mentioned, this is a thriving operation, and it plays a meaningful role for society. We have to consider where our resources should go. When you examine the expense structure, the issue I discovered inside the company isn't simply the total amount we're spending — it's the manner in which that money gets spent. There were quite a few pet projects floating around, along with other places where funds were being used. A key priority for me right now is getting the organization to concentrate. Which areas truly count? Where will expansion come from? How can we point our people and money toward those things? If something isn't among the top engines of growth, then in my view we need to take a hard look at whether we keep putting resources into it, or whether we explore alternatives for certain of those operations.
Umer Raffat
analystHey, everyone. I appreciate you letting me ask something. I'd like to dig into the infusion capacity with a bit more granularity. It seems like we've discussed this multiple times — the infrastructure has to get built out. Could we put a number on it — say, out of that 100K patients figure referenced in certain earlier press releases for year three, what portion is actually available right now? Would you be able to take an interim peek at your ongoing early AD study, which includes a monthly arm, to potentially shift the label toward monthly dosing? Might that occur at any point in the near term?
Christopher Viehbacher
executiveRegarding capacity, clearly Biogen achieved a fair amount of headway on this matter when ADUHELM launched. I'd say our position now is likely stronger than it was back at the ADUHELM launch. Even so, it's not as though numerous infusion centers sit empty awaiting Alzheimer's patients at present. Additional investment is going to be necessary, and that will require time. One factor behind our guidance of 100,000 patients is that the system is going to face limitations. It doesn't make much sense to discuss the potential — how many Alzheimer's patients exist and how many qualify. This has inherent limitations. On top of that, careful patient selection will be needed regarding who stands to gain the most from this treatment. Doctors are going to need time to grasp this new therapy and build familiarity with the drug; progress will be gradual and consistent. I can't provide you. I'd prefer not to address today how many sites there are, but this is clearly a significant element of the launch; that's the reason I describe it as not truly being a round white tablet of a launch.
Analyst
analystThe remaining item, I believe, concerned the possibility of administering maintenance doses less often, plus when that might happen. Priya, would you like to weigh in?
Priya Singhal
executiveCertainly. That's precisely it, Chris. Our view is that a portion of this infusion capability may be flexible, and there will be learning early on. As you noted, we'll figure things out as we proceed. There are two things to mention. First, Eisai is already taking the lead on a maintenance therapy; the regimen might follow either a 4-week or a 12-week schedule. They've stated openly that a filing will come by Q1 2024. That matters. A second item also under development, I'd say, is a formulation given subcutaneously. Eisai and Biogen are considering the burden a product such as LEQEMBI would place on people, and how we address that for patients and providers alike; that's truly the thinking driving the subcutaneous work. A Phase three sub-study is examining it right now, and a filing will happen too, by Q1 2024, as Eisai has said. We're attempting to approach this from several angles. Further updates will be shared once they're pertinent.
Evan Seigerman
analystHey, everyone. I appreciate you taking my question. Chris, during your comments, you pointed to a change in business development, while previously, Biogen might have been more reluctant to make acquisitions. What areas would you want BD to target, and what deal sizes would feel right to you? Thanks.
Christopher Viehbacher
executiveFrom a management standpoint, you need to consider what your team excels at. The interesting thing regarding Biogen is that it's been a company with a very narrow focus. They've excelled at what's been accomplished in multiple sclerosis, as an example. You must consider carefully how wide you expand, since we're extremely skilled at selling products that are high value and low volume. Even when we think about the zuranolone launch, we're going to be reaching a far broader population. We'll likely need much more patient outreach. In Biogen's entire history, I believe it has aired exactly one television commercial. That's something we'll need to become skilled at. When considering business development, you must ask, sure, you can examine opportunities on paper, but can you carry them out effectively? In my view, I'd prefer to be somewhat broader than the traditional neurodegenerative diseases, because I don't want to desert them at all. If that's your sole business, you're truly bound to conduct these long-term studies that cost a great deal. Frequently, phase three ends up being the proof of concept, since you can't genuinely test these things well in phase two. If I ask, where could we reasonably go? Where do we have some expertise? We can certainly be in immunology, because I'd contend that conditions like lupus, where we already operate, and even multiple sclerosis, are truly autoimmune diseases. I could see us expanding further into immunology. In psychiatry, we'll have one product secured, with zuranolone. Would expanding further into psychiatry be sensible? Clearly with SPINRAZA, when we consider how to extract more from SPINRAZA, when you're in the rare disease business, it differs from most other businesses. In most other therapeutic areas, you visit a physician because patients go to the physician. In rare diseases, you must go locate the patient. I recall at Genzyme, someone in marketing taught me very early that the marketing strategy involves searching for needles in haystacks. That genuinely becomes a core competency. That's one of the areas we must pursue. There are a great many patients who are easier to find, who are more severe, and who naturally see physicians. There are, for example, adult patients who are hard to diagnose. Aiming to grow patient numbers means we'll need to excel at rare diseases. So once you've got that fundamental capability, my perspective is that you're able to operate in rare disease, and within that space you can remain agnostic regarding both therapy and indication. That's the place we're beginning from, since I believe we have what it takes to deliver in those spaces. Might that take the form of an acquisition? It could be late-stage in-licensing. Every one of those options is something we could examine. As you know, I — and when I take a look, acquisitions haven't really been a component of Biogen's growth strategy, necessarily. That said, I put it to people this way: "There wasn't much reason to bring me on board if doing deals isn't something you want." So I'm not claiming that's what we're doing, but my sense is there's now a willingness inside the organization to at minimum give it a look at this point. As everyone is aware, M&A is difficult to pull off and to land something genuinely accretive that produces a return on investment. Which is exactly why we're putting our primary emphasis on squeezing as much as possible from organic growth. I'd put it this way: anything within those 4 areas I listed earlier is something we're open to.
Mike Hencke
executiveLet me jump in briefly on what you asked, Evan, about deal size. I won't say anything about how big a single transaction or a set of transactions could be, but if we're just talking total capacity — as we noted at the start, we closed out the year holding $5.6 billion in cash. Additional funds are arriving from Samsung during the early part of this year's second quarter, and our debt level is modest. It doesn't take long to arrive at a capacity figure approaching the better part of $10 billion that we could put to work in a number of different ways.
Christopher Viehbacher
executiveCall attention to the sum of money that is still coming to us from Samsung. That has not yet arrived.
Mike Hencke
executiveRight, so we're looking at $800 million arriving in April, followed by an additional 400+ that shows up the following year.
Christopher Viehbacher
executiveLook, having enough resources isn't really the biggest limitation. The truly difficult piece here is identifying something worth putting effort into.
Tim Anderson
analystThanks. I have a few questions regarding LEQEMBI and the subQ. Could you clarify the minimum regulatory requirements needed for a subQ approval—specifically, what must be demonstrated from the data you're gathering at present? Do you see any significant risk involved in collecting that required data? From my perspective, the brand's long-term commercial prospects truly depend on having a subQ, and I'm attempting to assess whether there is any substantial risk we ought to be aware of. Thank you.
Priya Singhal
executiveI can handle that one. I appreciate the question. So on the whole, what I'd like to do first is restate that Eisai is conducting research on subcutaneous administration within the phase 3 open label extension. The specifics of that sub-study, in fact, are available publicly. You're welcome to review them. Eisai has likewise stated its belief that the regulatory conversations needed to move forward along this pathway have already taken place. Going past that point, speculating about minimum requirements isn't something I can do. My sense is that regulatory talks are indeed continuing, and much of this, as you're aware, always hinges on the data as it emerges. Broadly speaking, Eisai has said it anticipates submitting a filing by Q1 2024. Now, pulling back to ask what the genuine potential looks like — I'd simply return us to what the Clarity AD study showed, which naturally involved the intravenous, bimonthly dosing schedule. What mattered most there, I'd say, was observing amyloid reduction at six months that continued expanding across the 18-month span. We achieved a positive primary endpoint with a B value that was highly statistically significant, plus every secondary endpoint; our view is that Clarity AD is really quite unambiguous in what it produced, and we hold that these findings carry meaning and can make a difference for the patient population. Thinking about the subcutaneous formulation is essentially how we approach this in a more comprehensive way. Our belief is that as it stands, substantial potential exists there, and naturally we'll keep advancing our work on dosing, maintenance dosing, and subcutaneous as well. As Chris brought up, what role might an anti-amyloid therapy play in pre-symptomatic or preclinical Alzheimer's disease?
Christopher Viehbacher
executiveSo Tim, here's how I see it: over time, I believe we'll end up with a phase focused on clearing plaque, followed by maintenance. Near term, sure, we could discuss what subQ might offer, but honestly, for the coming 2 to 3 years, the product's demand is likely constrained more by how much the system can handle when it comes to diagnosing and treating patients. An IV matters for patient convenience, though I doubt that in the near term it will move demand very much. To me, one real game changer is blood biomarkers. If we could do away with PET scans, and especially the lumbar puncture, that would make it far simpler for the entire medical community to at least secure the diagnosis, and we could likely bring down a patient's overall treatment cost; these blood biomarkers have existed for a while, yet until a treatment came along, no commercial market existed for such diagnostics. In my view, the greatest game changer possible would be getting some of these blood diagnostics to market faster. They're likely still 2 years out, but commercially, in my mind, they matter as much as a subQ.
Brian Abrahams
analystHi there, and good morning. I appreciate you taking my question. Regarding LEQEMBI, when you think about maintenance therapy, how should we properly frame the possible trade-off between yearly price reductions on a per-patient basis and the opportunity for the market to grow, along with better durability from chronic use? Thank you.
Christopher Viehbacher
executiveAre you referring to the price decrease tied to maintenance? Is that what you mean?
Brian Abrahams
analystWhen you're looking at a maintenance therapy, how do you factor in strategic pricing on an annualized basis compared with the every two week schedule? What's the right way to think about that overall balance?
Christopher Viehbacher
executiveAgain, I think it's clear that at this point we have to hold off, review the data, and obtain approval for these products. My sense is you'll probably remain within the plaque removal phase, which uses the every two weeks regimen. When you transition into maintenance, as Priya said, the dosing schedule could be different. Naturally, shifting from two weeks to one month would produce a lower total cost per patient when calculated on an annualized basis. My guess is that you may end up seeing patients pay less, just because the way dosing is scheduled changes across time. In the near term, though, my sense is that the number of people who could benefit probably exceeds what the system is capable of handling. I doubt we'll see much pressure on price. Down the road, after the system adjusts, that could change, but price doesn't strike me as the central issue here. Keep in mind, when you examine this, the figure we're citing is $26,500 covering the drug, yet treating patients adds considerably more expense for the system. Take a PET scan — that runs about $7,000, just to give one illustration. Since you already have the imaging and the therapy available, my view is that diagnostics done through blood draws might contribute more substantially when it comes to bringing total expenses down. Along those same lines, as we shift toward maintenance dosing and related regimens, it's possible we'll see the typical yearly spend per patient decline, even if the drug's list price itself stays where it is.
Michael Yee
analystHi there, appreciate you taking the question. Chris, good to hear your voice. In the slides, you said you'd want to see the risk profile and the productivity of the R&D pipeline get better, and specifically the risk profile. Back in January, as I remember it, you brought up projects of the lower-risk variety and suggested that maybe Biogen carries too much risk for the reward, especially given where this market cap sits. Thinking back to your earlier career, I believe you were involved with the Genzyme deal and also the Regeneron deal. Could you share your thinking on the philosophy behind acquiring products that might carry less risk, that are more de-risked, and how you approach bringing those in, executing on them, and doing so quickly? Thanks.
Christopher Viehbacher
executiveAbsolutely. For me, managing risk is simply part of the everyday job when you work at a pharma company. Obviously, nothing gets done without accepting some risk. We develop products at an early stage — with phase 1, say, your probability of success sits at 10%. There are, I'd say, a few areas we'd examine. First of all, clearly, when you're able to run a phase two study that gives you substantial confidence regarding safety and efficacy prior to entering a phase three study, then at essentially each stage of development — phase one into phase two, phase two into phase three — you've de-risked it. Sometimes that isn't possible. Take Alzheimer's, with the development of either lecanemab or ADUHELM: you can begin to observe, for example, that plaque is being reduced. A difficulty we faced, and many companies faced, was that plaque reduction wasn't sufficient. And you won't know whether you've reduced plaque sufficiently until a cognitive function benefit shows up. That's really not something you can determine until you run large studies over a long period, since these diseases advance so slowly. For me, one area is that we can... whether you're in autoimmune diseases or in psychiatry, you're able to pursue a more classical form of drug development, where phase two lets you de-risk more. You can obtain a proof of concept. As I mentioned before, we sometimes conduct proof of concept during phase three, which is a costly way of doing proof of concept. Merely considering a move into some of these other areas lets us carry out more classical drug development. The other thing, naturally, is that we can begin licensing in products that are, you know, considerably nearer to market, and on those you aren't assuming quite as much risk; it truly comes down to, when you examine it, how much is a precedented versus an unprecedented mechanism of action? How much involves small molecules versus large molecules? Could we adopt more collaborative sorts of approaches? You see, the idea that proof of concept should always happen during Phase three is an extremely costly and extremely risky way to operate. In my view, keeping a handful of those projects within our pipeline makes sense. When every single one of our pipeline projects falls into that category, well, that's difficult. If you examine it, we actually don't have any approval arriving in our pipeline for a number of years still, since we're dependent on those long-term studies. Having items that produce results somewhat more often would be useful for assessing the company's sustainable growth. Operator, I believe there's time for one last question.
Chris Schott
analystGreat, thank you very much. One more question about BD. Will you pursue that alongside the strategic review and the cost resizing work? Or does it become more of a longer-term priority once the necessary changes to the core business are made? As a second part to that same question, based on what you've said before about Biogen's narrow focus, does that suggest BD will lean more toward company acquisitions rather than partnerships, or toward earlier-stage deals? Because it sounds like you may want to bring in both products and expertise, so just give me a little help with how you're thinking about that dynamic. Thank you.
Christopher Viehbacher
executiveDuring the opening six months of 2025, our clear focus has been on steering the organization toward avenues for growth and taking a close look at our expense structure. In that window, we should have somebody new leading research. A head of BD is also being brought on board at the moment. Personally, that's the kind of area we start digging into once we're in the back half of the year. As everyone knows, locating opportunities doesn't happen overnight. Prior to taking action, there's a great deal you need to review. Even if your intention is to move on something in the following year, the search really has to begin right away. As for the areas we're reviewing — well, any combination of them is possible. If we start feeling good about how LEQEMBI and zuranolone are rolling out, then sure, you could make the case — the bankers love talking about this "desperation factor." My take is that ours isn't high at all. There's plenty we can accomplish internally. Still, I believe it's a good thing to keep an eye on the outside and maintain options, since in this industry, things rarely unfold exactly as you expect. We've got the luxury of time to evaluate and confirm that anything we pursue will add value, and I think it could end up being every one of the possibilities you listed.
Analyst
analystAlright, that brings us to the end of today's call, I believe. Thanks to all of you for being with us.
Operator
operatorThis concludes today's call. Thank you for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.